Real-world effectiveness of risankizumab in psoriasis: first Sardinian multicenter 2-year experience

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Psoriasis is a chronic, immune-mediated skin disease impacting quality of life.
• Risankizumab, an anti-IL-23 monoclonal antibody, offers effective treatment with a good safety profile.
• Real-world psoriasis treatment is influenced by healthcare system constraints and prior treatment failures.

Purpose of the Study:

• To evaluate the effectiveness and safety of risankizumab in a Sardinian psoriasis patient cohort.
• To assess long-term outcomes of risankizumab treatment over 6, 12, and 24 months.
• To analyze treatment response based on patient characteristics like prior biologic use and disease duration.

Main Methods:

• Prospective, multicenter study (ESSOS-BIO-PSO) in Sardinian psoriasis centers.
• Recruited 73 patients with moderate-to-severe psoriasis treated with risankizumab for at least 6 months.
• Monitored effectiveness (PASI-90) and safety over 24 months.

Main Results:

• 74% achieved PASI-90 at 52 weeks, increasing to 76.7% at 104 weeks; all sustained response.
• Biologic-naïve patients and those with shorter disease duration showed faster, statistically significant responses.
• Risankizumab was well-tolerated with 100% adherence and no severe adverse events.

Conclusions:

• This Sardinian study confirms durable effectiveness and excellent adherence for risankizumab in moderate-to-severe psoriasis.
• Treatment outcomes were consistent regardless of prior treatments or comorbidities.
• Biologic-naïve patients demonstrated a quicker response to risankizumab therapy.